Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Camonsertib | ATM/ATR | TargetMol
Camonsertib | RP-3500 | ATR Inhibitor | Anti-tumor | TargetMol
Camonsertib | C21H26N6O3 | CID 156487652 - PubChem
N-Glucuronide Metabolite of Camonsertib - Hypha Discovery
´Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP ...
(PDF) Camonsertib in DNA damage response-deficient advanced solid ...
Camonsertib – Application in Therapy and Current Clinical Research
Camonsertib in DNA damage response-deficient advanced solid tumors ...
Camonsertib
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP ...
Camonsertib | Proteintech | 武汉三鹰生物技术有限公司
Camonsertib (RP-3500) | ATR Inhibitor | CAS 2417489-10-0 | Selleck ...
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose ...
First Patient Enrolled in Monotherapy Study Evaluating Camonsertib in ...
MYTHIC: lunresertib and camonsertib in ovarian and endometrial cancers ...
Combination of camonsertib plus PARPi shows clinical activity in DDR ...
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non ...
BIOTECH (77) – Repare Therapeutics: Camonsertib (ATR inhibitor ...
Identification and Biosynthesis of an N-Glucuronide Metabolite of ...
camonsertib(2417489-10-0) 1H NMR spectrum
Exceptional response to the ATR inhibitor, camonsertib, in a patient ...
Full article: Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK ...
Development of a Practical Nomogram for Personalized Anemia Management ...
Targeting the DNA damage response prevents regrowth of colorectal ...
FDA Fast Tracks Lunresertib/Camonsertib in Platinum-Resistant Ovarian ...
Lunresertib/Camonsertib Gets Fast Tracked by FDA for CCNE1+ or FBXW7 ...
Table 1 from Identification and Biosynthesis of an N-Glucuronide ...
DNA損傷応答異常のある固形癌に3種類のPARP阻害薬とATR阻害薬camonsertibの併用は有望【AACR 2023】｜日経メディカル
Camonsertib(Camonsertib) - 药物靶点：ATR_在研适应症：非小细胞肺癌，肝转移，转移性实体瘤_专利_临床_研发
DNA損傷応答異常のある固形癌に3種類のPARP阻害薬とATR阻害薬camonsertibの併用は有望【AACR 2023】：がんナビ
(Camonsertib)-药物靶点：ATR_在研适应症：晚期恶性实体瘤，实体瘤，子宫内膜癌_专利_临床_研发
Comparison of selected clinical-stage ATR inhibitors as monotherapy ...
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid ...
MetID Services - Hypha Discovery
Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I ...
Small Molecule Highlights #21 – February 2024 – Dalriada Drug Discovery
SOX2-high cancer cells exhibit an aggressive phenotype, with increases ...
Fast Track Designation Granted by the FDA for Lunresertib in ...
ATR Kinase Assay Service - Reaction Biology
Repare Therapeutics Announces Positive Results of the Lunresertib and ...
Abstract B025: Exceptional response to the ataxia telangiectasia and ...
ATM/ATR | 抑制剂 | MCE
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor ...
合成致死靶点持续火热：罗氏与Repare达成13亿美元合作 2022年6月1日，罗氏宣布与 Repare Therapeutics 就后者的 ...
突破性研究：ATR抑制剂camonsertib在治疗晚期实体肿瘤中显示出巨大潜力-抗癌药-瑞得生健康网
Overview of the TRESR trial: a CRISPR–Cas9 chemogenomic-informed ...
We’re excited to share the publication of our pre-clinical paper in ...
Lunresertib联合Camonsertib：子宫内膜癌与卵巢癌靶向治疗新希望 - MedFind
超过13亿美元！罗氏与Repare就 Camonsertib开发达成全球许可和合作协议|修复|全球|开发|肿瘤|抑制剂|-健康界
Camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor.
正在临床中的DNA 损伤反应抑制剂有哪些？ - 知乎
Molecular modeling of a close-up view of the interactions between the 7 ...
.jpg?fit=crop&auto=format)
